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Abstract
Background: The aim of this study was to determine the efficacy and safety of levosimendan 
in takotsubo cardiomyopathy (TC).
Methods: The study was conducted in a retrospective design and 42 consecutive patients were 
enrolled in 6 cardiovascular centers in Turkey. The records of TC patients having left ven-
tricular ejection fraction (LVEF) £ 35% were examined at admission, discharge and recovery 
period including their clinical and echocardiographic data. 
Results: Of these 42 TC patients, 17 were treated with loading dose and i.v. infusion of levo-
simendan (group 1) and 25 were treated without levosimendan (group 2). Echocardiographic 
findings at admission and at discharge were similar and no serious complications were 
observed in either group. However recovery period including the interval of 50% increase in 
LVEF, time to achieve the baseline troponin values and hospitalization were significantly lower 
in patients taking levosimendan.
Conclusions: This is the first study using loading dose and subsequent continuous intrave-
nous administration of levosimendan demonstrating accelerated recovery in patients with TC. 
(Cardiol J 2016; 23, 6: 610–615)
Key words: takotsubo cardiomyopathy, levosimendan, recovery, heart failure, 
stress cardiomyopathy
Introduction
Takotsubo cardiomyopathy (TC), also known 
as stress cardiomyopathy, left ventricular (LV) api-
cal ballooning syndrome or broken heart syndrome, 
is a unique cardiac situation characterized by tran-
sient LV systolic dysfunction often mimicking an 
acute myocardial infarction. In most cases the un-
derlying factor can be elaborated as acute emotional 
and/or physical stress and it is characterized by 
three distinctive features: (a) the presence of acute 
LV wall dysfunction, (b) the absence of significant 
obstructive coronary artery disease and (c) the 
rapid improvement of LV systolic function within 
a few days or weeks [1, 2]. The clinical presentation 
of TC causes a significant risk for adverse events 
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and thus represents an acute heart failure [3]. Al-
though the acute course of TC is not malignant in 
most cases, 20% face some complications such as 
ventricular tachycardia, ventricular thrombus and 
ventricular rupture similar to, or higher than those 
of patients with acute coronary syndrome during 
their hospital stay.
The underlying mechanism of TC still remains 
unclear but many hypotheses including multi-
vessel coronary artery spasm, coronary microvas-
cular dysfunction or catecholamine toxicity, have 
been introduced. In the clinical setting, TC is an 
important disease that must be promptly differenti-
ated from acute myocardial infarction to enable its 
appropriate management [4].
Levosimendan is a powerful inhibitor of phos-
phodiesterases but its positive inotropic effect is 
achieved without a significant increase of intracel-
lular cAMP and Ca2+. This calcium-sensitizer drug 
reinforces the Ca2+-binding with troponin-C during 
systole and improves ventricular relaxation during 
diastole as the so-called lusitropic effect; moreover, 
this levosimendan shows important anti-stunning 
and vasodilator effects by opening the ATP-sen-
sitive K+-channels [5]. Previously levosimendan 
had been proposed as the choice of inotropic 
drug by Santoro et al. [6] and to our knowledge, 
levosimendan was the pivotal therapeutic agent 
in treatment of TC. Herein, we retrospectively 
compared the acute course of TC patients treated 
versus untreated with the loading dose and infusion 
of levosimendan.
Methods
A total of 42 subjects were enrolled in a re-
strospective manner between January 1st 2010 to 
July 31st 2016 at 6 centres in Turkey. The records of 
42 TC patients having LV ejection fraction (LVEF) 
£ 35% were examined. Mayo diagnostic criteria [7] 
was utilized where all the four items were manda-
tory for accurate diagnosis: 
 — Transient LV dysfuntion (hypokinesis, akine-
sis, or dyskinesis): The wall motion abnormali-
ties are typically regional and extend beyond 
a single epicardial coronary distribution; rare 
exceptions are the focal (within one coronary 
distribution) and the global type;
 — Absence of obstructive coronary disease or 
angiographic evidence of acute plaque rupture: 
If coronary disease is found, the diagnosis of 
stress cardiomyopathy can still be made if the 
wall motion abnormalities are not in the distri-
bution of the coronary disease. This exception 
is made since some patients with stress cardio-
myopathy have concurrent coronary disease;
 — New electrocardiographic abnormalities (ei-
ther ST-segment elevation and/or T wave 
inversion) or modest elevation in cardiac 
troponin;
 — Absence of pheochromocytoma or myocarditis.
Of the 42 patients, 17 patients (female: 12) 
were treated with intravenous (i.v.) continuous 
infusion of levosimendan within the first 24 h after 
admission in 2 centres as a routine therapy; infu-
sion rate was 0.1 µg/kg/min with 10 µg/kg loading 
dose for 24 h. The loading dose was used as a stand-
ard levosimendan therapy for all patients without 
hypotension (systolic/diastolic blood pressure 
< 90/60 mm Hg). Twenty five patients (female, n = 18) 
were treated without i.v. continuous infusion of 
levosimendan in the other 4 centres. All patients 
were administered a standard of care including 
angiotensin converting enzyme inhibitor/angio-
tensin receptor blockers and beta-blocker unless 
contraindicated. Medical records, including medi-
cal history, physical examination, laboratory tests, 
coronary angiography, 12-lead electrocardiogram 
(ECG) also echocardiographic findings for cases in 
which they were available were carefully reviewed. 
The following data were obtained by analyzing age, 
gender, physical — emotional stress factors, days 
of hospitalization and coronary risk factors includ-
ing smoking, hypertension (as defined by the Joint 
National Committee VIII) [8], diabetes mellitus (as 
defined by the World Health Organization study 
group) [9], dyslipidemia was considered present if 
the total cholesterol concentration on admission 
was higher than 220 mg/dL or the low-density 
lipoprotein cholesterol concentration on admission 
was higher than 140 mg/dL and a family history 
of premature coronary artery disease defined as 
myocardial infarction or sudden death in a first 
relative, male < 55 years and female < 65 years.
All patients underwent continuous ECG and 
hemodynamic monitoring for 48 h.  Troponin I lev-
els were measured for all patients using a chemi-
luminescent immunoenzymatic assay (Access 
AccuTnI, Beckman Coulter, Fullerton, CA, USA). 
The detection limit of this assay is 0.01 ng/mL and 
the 99th percentile in an apparently healthy refer-
ence population is reported to be 0.04 ng/mL. Pa-
tients underwent coronary angiography procedure 
which showed the absence of coronary disease. 
Transthoracic echocardiography examination was 
performed in all patients at admission, during the 
hospital stay and at discharge. LVEF was calculated 
using the biplane method (modified Simpson’s rule) 
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from the apical 4-chamber and 2-chamber views. 
LVEF recovery to > 50% was the only criterion 
for discharge from hospital. The study protocol 
was in agreement with the guidelines of the ethics 
committee of aforementioned institutions.
Statistical analysis
All data are expressed as mean ± standard 
deviation. Distributions of continuous variables in 
the two groups were compared with either the un-
paired t test or the Mann-Whitney U-test according 
to whether data followed the normal distribution. 
Comparison between the two groups was per-
formed by using the c2 test for categorical variables. 
ANOVA test was used where > two groups were 
present to compare. Missing values were replaced 
by multiple regression imputation. All tests were 
performed with IBM SPSS for Windows, version 
21.0. (Chicago, USA). All results were considered 
statistically significant at the level of p < 0.05.
Results
Retrospectively 42 consecutive patients were 
enrolled and diagnosed with TC and of these, 
17 were treated with levosimendan (group 1) and 
25 were treated without levosimendan (group 2). 
Baseline characteristics listed in Table 1 were 
similar in both groups. Triggers of TC such as 
physical and emotional stress were also similar in 
both groups (p = 0.453).
Only 1 patient was admitted with cardiogenic 
shock and she was treated with levosimendan plus 
dopamine. Fortunately she has recovered quite 
well. No serious complications including arrhyth-
mia were observed in either groups.
Echocardiographic findings at admission and 
discharge were similar in both groups (Table 2). 
In group 1, the mean LVEF at admission was 
32.3 ± 3.1% and  32.0 ± 3.8% in group 2 (p = 0.754). 
All patients showed improvement in LVEF during 
discharge where mean LVEF at discharge was 57.3 ± 
± 5.0% in group 1 and 55.2 ± 4.4% in group 2 
(p = 0.152). 
However, the recovery period significantly 
differs between the two groups (Table 3). The time 
to LVEF rise above 50% was significantly lower in 
group 1 compared to group 2 (8.3 ± 1.9 days vs. 
10.8 ± 3.1 days, p = 0.001). Hospitalization time also 
showed statistical significance (lower in group 1) 
compared to group 2 (9.4 ± 1.7 days vs. 14.3 ± 1.5 
days, p < 0.001). The recovery time to baseline 
Table 1. Baseline characteristics.
Variable Group 1 (n = 17) Group 2 (n = 25) P 
Age [years] 59.2 ± 10.9 63.3 ± 6.5 0.140
Sex (female) 12 (70.6%) 18 (72%) 0.065
Body mass index [kg/m2] 26.7 ± 4.1 28.6 ± 4.5 0.186
Hypertension 5 (29.4%) 9 (36%) 0.666
Dyslipidemia 1 (5.9%) 1 (4%) 0.143
Diabetes mellitus 5 (29.4%) 5 (20%) 0.494
Smoking 7 (41.2%) 13 (52%) 0.503
Emotional stress 13 (76.5%) 15 (60%) 0.082
Physical stress 4 (23.5%) 10 (40%) 0.065
Systolic arterial pressure [mm Hg] 115 ± 28 118 ± 25 0.176
Diastolic arterial pressure [mm Hg] 73 ±11 74 ± 10 0.172
Heart rate [bpm] 88 ± 25   86 ± 27 0.184
Troponin levels [ng/dL] 6.9 ± 3.1 7.3 ± 3.0  0.628 
Medications:
ACEI/ARB 17 (100%) 24(96.0%) 0.147
Beta-blocker 15 (88.2%) 21 (84.0%) 0.068
Spironolactone 8 (47.1%) 12 (48.0%) 0.854
Diuretic (furosemide) 2 (11.8%) 3 (12.0%) 0.912
(+) inotropes including dopamine and dobutamine 1 (5.9%) 0 (0%) < 0.001
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blockers
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troponin values were also significantly lower in 
group 1 compared to group 2 (5.1 ± 1.6 days vs. 
8.2 ± 2.4 days, p = 0.001).
Discussion
This study evaluated the efficacy of the treat-
ment strategy with levosimendan compared to 
standard therapy in TC patients with severe LV 
dysfunction independent of baseline blood pres-
sure. Actually, this is the first study investigating 
the efficacy of loading dose followed by the i.v. 
continuous infusion of levosimendan in TC setting. 
We have found that all patients were safely treated 
with i.v. infusion of levosimendan and also it has 
reduced hospital stay and recovery to baseline 
clinical parameters.
In the literature, there were only a few le-
vosimendan (without loading dose) treated TC 
cases that were complicated with cardiogenic shock 
[10–13]. However in this present study, none of 
the patients in both groups were complicated by 
cardiogenic shock and all were treated with loading 
dose of levosimendan. In a comprehensive case 
series recently published by Santoro et al. [6], 
it was evaluated that the use of levosimendan 
without loading dose in patients with TC might 
be safe and feasible with low rates of adverse 
events. Herein, we used loading dose and found 
similar results with this study. Santoro et al. [6] 
have also demonstrated that mean hospital stay 
of patients treated with levosimendan was 10 ± 
± 4 days and was quite similar to results found 
in this study (9.4 ± 1.7 days). Additional findings 
disclosed that time to recovery to the baseline 
troponin values and time to LVEF rise above 50% 
were significantly lower in patients treated with 
levosimendan.
Levosimendan infusion was well tolerated in 
group 1 patients. No malignant cardiac arrhythmias 
were observed and none of the patients developed 
LV outflow tract obstruction. LVEF improved in 
all patients independent of treatment with levosi-
mendan, however LVEF improvement was faster 
in the patients treated with levosimendan.
Levosimendan is a new molecule with both in-
otropic and vasodilator effect. The main mechanism 
of action described for this drug is elaborated as 
the increase in the troponin C affinity for Ca2+ and 
the stabilization of troponin C conformation. The 
administration of this calcium sensitizer presents 
other effects such as peripheral vasodilatation, anti-
ischaemic benefits and cardioprotection [14]. The 
main mechanism of increasing myocardial contrac-
tilityis based on the increase of sensitivity of car-
diac troponin C towards intra-cytoplasmic calcium 
[15–18]. Experimental studies have demonstrated 
that levosimendan has a preconditioning-like effect 
Table 3. Recovery of patients in both groups.
Variable Group 1  
(n = 17)
Group 2  
(n = 25)
P 
Hospital stay [days] 9.4 ± 1.7 14.3 ± 1.5 < 0.001
Time to recover to the baseline troponin values [days] 5.1 ± 1.6 8.2 ± 2.4 0.001
Time to rise in left ventricular ejection fraction above 50% [days] 8.3 ± 1.9 10.8 ± 3.1 0.001
Table 2. Echocardiographic findings at admission and at discharge.
Group 1 (n = 17) Group 2 (n = 25) P
Admission Discharge Admission Discharge
AoD [mm] 27.0 ± 2.3 26.9 ± 2.8 29.2 ± 1.4 25.8 ± 2.8 0.216
LAD [mm] 38 ± 2.7 35.9 ± 1.8 32 ± 2.7 37.1 ± 4.6 0.306
LVEDD [mm] 51.6 ± 2.1 50.1 ± 2.6 51.1 ± 6.1 49.3 ± 6.1 0.635
LVESD [mm] 36.0 ± 3.2 31.0 ± 1.8 34.1 ± 9.1 30.4 ± 8.3 0.430
IVSD [mm] 10.3 ± 1.1 10.9 ± 3.8 10.2 ± 1.2 10.8 ± 3.6 0.143
PWD [mm] 10.5 ± 1.8 10.7 ± 3.4 10.8 ± 2.3 10.9 ± 2.9 0.096
LVEF [%] 32.3 ± 3.1 57.3 ± 5.0 32.0 ± 3.8 55.2 ± 4.4 0.152
AoD — aortic root diameter; LAD — left atrial diameter; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic 
diameter; IVSD — interventricular septum diastolic dimension; PWD — posterior wall dimension; LVEF — left ventricular ejection fraction
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on myocardial function [19] as it protects the heart 
against ischaemia and reperfusion damage by the 
opening of cardiac mitochondrial ATP-sensitive po-
tassium [mito.K (ATP)] channels, one of the main 
mediators of cell protection pathways [20]. This 
mechanism of positive inotrophic myocardial con-
traction strengthening occurs without increasing 
oxygen demand, intracellular cAMP or intracellular 
calcium concentration at clinically relevant doses 
[21–23]. Levosimendan activates the opening of 
ATP-sensitive K+ channels of smooth muscle cells 
allowing their hyperpolarization by leveraging 
vasodilation [24, 25]. These vasodilatory properties 
lead to a dramatic increase in cardiac output with 
a concomitant reduction in cardiac filling pressures 
in the failing heart to enable it to generate more 
efficient systolic and diastolic functions [26, 27]. 
All these mechanisms mentioned above may con-
tribute to more rapid improvement of ventricular 
functions and clinical recovery in patients who 
were treated with levosimendan in this study.
There are case reports of successful levo-
simendan use in cardiomyopathy due to acute 
Chagas’ disease, peri-partum cardiomyopathy, 
anthracycline-induced cardiotoxicity and TC 
[6, 10–13, 28–30]. In the present study, it was 
demonstrated that levosimendan can be used safely 
and efficiently in TC as a non-catecholaminergic 
inotrope agent for faster symptomatic and clinical 
improvement for the first time.
Limitations of the study
Our results indicate that levosimendan may 
have positive effects in TC with a loading dose 
safely and efficiently. The present study, however, 
has some limitations due to the small number 
of patients and its retrospective nature. Further 
prospective randomized studies enrolling more 
patients are needed to validate these results.
Conclusions
This is the first study using loading dose and 
subsequent continuous intravenous administra-
tion of levosimendan demonstrating accelerated 
recovery in patients with TC.
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